2022-09-29-世界卫生组织-A_H7N9_-_Southern_hemisphere_2023_3页_208kb

Summary of H7N9 Candidate Vaccine Virus Status

This report, dated 28 September 2022, outlines the current status of development and availability for avian influenza A(H7N9) candidate vaccine viruses and potency testing reagents as part of the WHO Global Influenza Surveillance and Response System (GISRS). Antigenic and genetic analyses are conducted by WHO Collaborating Centres, and all candidate vaccine viruses listed have successfully passed two-way haemagglutination inhibition (HI) tests, ensuring they meet criteria for safety and suitability. These viruses require BSL-2 enhanced containment due to safety protocols and are available from key institutions such as FDA CBER, CDC, NIBSC, CCDC, NIID, and SJCRH. Reference antigens and antisera are provided for potency testing and quality control, with specific batch numbers and origins listed, and requests are evaluated on a case-by-case basis.

• Key Virus Strains Covered: A/Guangdong/17SF003/2016, A/Hong Kong/125/2017, A/Shanghai/2/2013, A/Anhui/1/2013, and preparation for A/Hunan/02650/2016.
• Developer Institutions: CDC, FDA CBER, NIBSC, CCDC, NIID, SJCRH under WHO support.
• Regulatory Note: National or regional control authorities must approve vaccine composition and formulation in respective countries.
• Contact Information: Provided for ordering candidate viruses or reference reagents.

For detailed lists of viruses, reagents, and specific contacts, refer directly to https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/zoonotic-influenza-viruses-and-candidate-vaccine-viruses. Inquiries can be sent to gisrs-whohq@who.int.